The estimated Net Worth of Kelly Mac Donald is at least $428 mil dollars as of 10 February 2024. Ms Donald owns over 5,333 units of Dynavax Technologies stock worth over $83,920 and over the last 5 years she sold DVAX stock worth over $343,634.
Sign up
Ms MacDonald DVAX stock SEC Form 4 insiders trading
Ms has made over 10 trades of the Dynavax Technologies stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 5,333 units of DVAX stock worth $58,183 on 10 February 2024.
The largest trade she's ever made was selling 22,714 units of Dynavax Technologies stock on 8 October 2020 worth over $238,497. On average, Ms trades about 3,058 units every 91 days since 2019. As of 10 February 2024 she still owns at least 7,692 units of Dynavax Technologies stock.
You can see the complete history of Ms Donald stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Kelly MacDonald biography
Kelly MacDonald is the Sr. VP & CFO at Dynavax Technologies.
How old is Ms MacDonald?
Ms MacDonald is 37, she's been the Sr. VP & CFO of Dynavax Technologies since . There are 5 older and no younger executives at Dynavax Technologies. The oldest executive at Dynavax Technologies Corp. is Michael S. Ostrach, 69, who is the Advisor.
What's Ms MacDonald's mailing address?
Kelly's mailing address filed with the SEC is C/O DYNAVAX TECHNOLOGIES, 2100 POWELL STREET, SUITE 720, EMERYVILLE, CA, 94608.
Insiders trading at Dynavax Technologies
Over the last 21 years, insiders at Dynavax Technologies have traded over $196,839,440 worth of Dynavax Technologies stock and bought 2,463,112 units worth $11,318,051 . The most active insiders traders include Andrew A. F. Hack, Partners L P/Ilbiotechnolog..., eJames Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $1,533,390. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth $43,127.
What does Dynavax Technologies do?
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
What does Dynavax Technologies's logo look like?
Complete history of Ms Donald stock trades at Dynavax Technologies e Ironwood Pharmaceuticals Inc
Dynavax Technologies executives and stock owners
Dynavax Technologies executives and other stock owners filed with the SEC include:
-
Ryan Spencer,
CEO & Director -
David F. Novack,
Pres & COO -
Dr. Robert Janssen,
Chief Medical Officer and Sr. VP of Clinical Devel., Medical & Regulatory Affairs -
Michael S. Ostrach,
Advisor -
John Slebir,
Sr. VP & Gen. Counsel -
Nicole Arndt,
Sr. Mang. of Investor Relations -
Meg Smith,
VP Sales & Operations -
Steven N. Gersten,
Chief Ethics & Compliance Officer, Sr. VP, Gen. Counsel and Sec. -
Heather Rowe,
VP of Investor Relations & Corp. Communications -
Jeff P. Coon,
Sr. VP of HR & Admin. -
Justin Burgess,
Principal Accounting Officer & Controller -
Kelly MacDonald,
Sr. VP & CFO -
Laura Brege,
Director -
Eddie Gray,
CEO and Director -
Arnold L Oronsky,
Director -
Stanley A Plotkin,
Director -
Daniel L Kisner,
-
Dennis Carson,
Director -
Natale S Ricciardi,
Director -
David Louis Johnson,
Vice President -
Michael S Ostrach,
Senior Vice President -
Elaine D Sun,
-
Francis Cano,
-
Peter R. Paradiso,
-
Peggy V Phillips,
-
Brent Mac Gregor,
-
Julia Marie Eastland,
-
Scott Dunseth Myers,
-
Partners L P/Ilbiotechnolog...,
-
Nest Gary A Van,
Vice President -
Dino Dina,
President and CEO -
Denise Gilbert,
Director -
Martin E Sanders,
EVP, Chief Development Officer -
James Edeerfield Capital Lp...,
-
Partners L P/Ilbiotechnolog...,
-
James Edeerfield Capital Lp...,
-
James Edeerfield Capital Lp...,
-
Deborah A Smeltzer,
VP Operations & CFO -
Timothy G Henn,
Vice President -
Zbigniew Janowicz,
Director -
Daniel Janney,
Director -
Stephen F Tuck,
Vice President -
Nancy L Buc,
Director -
J Tyler Martin,
VP Clinical Development & CMO -
Christine R Larson,
VP and Chief Financial Officer -
Capital Partners Lpsymphony...,
-
Jennifer Lew,
VP, Finance & PAO -
Mark Kessel,
Director -
David M Lawrence,
Director -
Daniel J Levitt,
VP and Chief Medical Officer -
James Edeerfield Capital Lp...,
-
Louis C Bock,
Director -
Jan Leschly,
Director -
James E Flynn,
10% owner -
Danielalta California Partn...,
-
Robert Coffman,
VP & Chief Scientific Officer -
David F Novack,
President & COO -
Ryan Spencer,
CEO and Director -
Robert Janssen,
SVP and CMO -
Kelly Mac Donald,
SVP and CFO -
Justin Burgess,
VP Finance & CAO -
Andrew A. F. Hack,